Medicare Payments For Hospital Outpatient Drugs Set At ASP+6% For 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS issues its final 2013 hospital outpatient prospective payment system rule for Medicare Part B. The ASP+6% payment rate for drugs is aimed at producing more predictable reimbursement for separately billable drugs, biologics and radiopharmaceuticals.
You may also be interested in...
Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.
Medicare Default Payment Of ASP+6% For Hospital Outpatient Drugs Has Industry Support
CMS says default for reimbursement of Medicare Part B drugs used in hospital outpatient settings will be average sales price plus 6% as it seeks to improve methods of calculating a proper reimbursement rate based on data provided by hospitals. The rate has fluctuated year-to-year, from ASP+4% to ASP+6%, under the previous formula.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.